TRVI - CONSENSUS CO - Trevi Therapeutics

The current state of Trevi Therapeutics (TRVI) is supported by an inflow of investment while clinical trials for new itch and cough remedies remain in the development stage. This price chart reflects a value of 29.44, while growth potential is based on a lack of competitors and hopes for rapid FDA approval of the drug Haduvio. The business relies on the unique nalbuphine ER molecule, which creates a closed treatment system.

Investors are assessing the potential of Trevi Therapeutics (TRVI) through the expected asset value upon the market launch of its drugs. This indicator represents the arithmetic mean of target prices from specialized agencies, reflecting the business's fundamental value over a one-year horizon. The trend in the consensus price target reveals anomalous shifts in market expectations. For this pharmaceutical company, this reflects the market's confidence in the future pricing power of its unique molecules. The growth of this metric confirms the investment attractiveness of its innovations.